Merck invests more than € 300 million into a new Bioprocessing Production Center in Daejeon, South Korea. The new site is the largest investment by Merck’s Life Science business sector in Asia-Pacific to date and demonstrates the company’s commitment to…
Merck will open a new, € 20 million distribution center in Cajamar, São Paulo, Brazil to better serve its Life Science customers in the region. The new space, which will be operational in late February, has an area of 13,000…
Supported by the Singapore Economic Development Board (EDB), the Digital Hub aims to propel advancements within the healthcare and semiconductor industries. Singapore is recognized globally for driving innovation and digital excellence, particularly in key areas such as digital health, semiconductor…
Merck Healthcare today announced a licensing agreement with Inspirna, Inc. for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds. Ompenaclid is currently being evaluated in a Phase II study for the second-line…
Merck Healthcare, a leading science and technology company, and the Pediatric Praziquantel Consortium today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive scientific opinion for arpraziquantel for the…
Merck Group today launched its AIDDISON™ drug discovery software, the first software-as-a-service platform that bridges the gap between virtual molecule design and real-world manufacturability through SynthiaTM retrosynthesis software application programing interface (API) integration. It combines generative AI, machine learning and…
Merck Healthcare today announced a license agreement with Abbisko Therapeutics Co. Ltd, Shanghai, China, for pimicotinib (ABSK021), which is currently being evaluated in a Phase III study for the treatment of tenosynovial giant cell tumor (TGCT). TGCT is a benign…
Merck Healthcare has launched ChemisTwin™, the first digital reference materials platform that can perform automatic analysis of samples’ purity, identification, and degradation of compounds through calibrated algorithm-based digital references. With digital signatures for more than 1,500 reference materials, this automation…
Merck Healthcare, will cover 100% of its current electricity purchases in the EU and Switzerland with renewable energy certificates from 2025 onwards. To this end, the company has signed virtual power purchase agreements for a total of around 300 gigawatt…
Merck Healthcare today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui). The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167.…